Alexis Borisy is founder and chief executive officer of EQRx. A former partner at Third Rock Ventures, Alexis is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Alexis joined Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He has played key roles in launching and building several of Third Rock’s portfolio companies. He was the chairman of the board, co-founder and interim chief executive officer of Foundation Medicine, interim CEO of Warp Drive and Blueprint Medicines, and currently serves as a board member of Foundation Medicine, Warp Drive Bio, Blueprint Medicines, Editas Medicine and Revolution Medicine.

Prior to joining Third Rock Ventures, Alexis founded CombinatoRx in 2000, serving as its chief executive officer and bringing the company public on the NASDAQ. He has raised billions in financing and business development deals and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.

Alexis’ undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis is a trustee of the Boston Museum of Science and a co-founder and former chairman of FORMA Therapeutics.